- Home
- ETON vs SITC Comparison
ETON vs SITC Comparison
Compare ETON & SITC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETON
- SITC
- Stock Information
- Founded
- ETON 2017
- SITC 1965
- Country
- ETON United States
- SITC United States
- Employees
- ETON 31
- SITC N/A
- Industry
- ETON Biotechnology: Pharmaceutical Preparations
- SITC Real Estate Investment Trusts
- Sector
- ETON Health Care
- SITC Real Estate
- Exchange
- ETON Nasdaq
- SITC Nasdaq
- Market Cap
- ETON 498.8M
- SITC 461.0M
- IPO Year
- ETON 2018
- SITC 1993
- Fundamental
- Price
- ETON $18.25
- SITC $8.38
- Analyst Decision
- ETON Strong Buy
- SITC Hold
- Analyst Count
- ETON 3
- SITC 4
- Target Price
- ETON $29.67
- SITC $13.13
- AVG Volume (30 Days)
- ETON 261.2K
- SITC 924.2K
- Earning Date
- ETON 11-06-2025
- SITC 11-05-2025
- Dividend Yield
- ETON N/A
- SITC 67.65%
- EPS Growth
- ETON N/A
- SITC N/A
- EPS
- ETON N/A
- SITC 6.74
- Revenue
- ETON $58,181,000.00
- SITC $173,351,000.00
- Revenue This Year
- ETON $105.25
- SITC N/A
- Revenue Next Year
- ETON $40.84
- SITC N/A
- P/E Ratio
- ETON N/A
- SITC $1.22
- Revenue Growth
- ETON 85.40
- SITC N/A
- 52 Week Low
- ETON $8.24
- SITC $8.41
- 52 Week High
- ETON $23.00
- SITC $17.14
- Technical
- Relative Strength Index (RSI)
- ETON 46.28
- SITC 36.93
- Support Level
- ETON $18.00
- SITC $8.41
- Resistance Level
- ETON $18.92
- SITC $8.91
- Average True Range (ATR)
- ETON 0.87
- SITC 0.18
- MACD
- ETON -0.12
- SITC 0.03
- Stochastic Oscillator
- ETON 40.66
- SITC 14.81
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
About SITC SITE Centers Corp.
SITE Centers Corp is a self-administered and self-managed REIT that operates as a fully integrated real estate company. The company is engaged in the business of owning, leasing, acquiring, redeveloping, developing and managing shopping centers.